According to Halozyme, the new version of Keytruda infringes on its patents, the report said. USAID cuts put tuberculosis response in peril, WHO says The Trump administration's decision to pause U.S.
New milestone achieved in Astellas T-cell engager collaboration: In February 2025, Astellas advanced the second program to ...
Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback